Pharmaceutical Product Monograph: Fluconazole Capsules (150 mg / 200 mg)
In the pharmaceutical industry, Fluconazole is a first-generation Triazole Antifungal agent. As a pharmacist and manufacturer, I classify this as a “Systemic Ergosterol Synthesis Inhibitor.” It is the most widely prescribed antifungal worldwide because of its excellent bioavailability (over 90% is absorbed orally) and its ability to penetrate the blood-brain barrier.
At your WHO-GMP facility in Mumbai, Fluconazole is a high-volume “Essential Medicine.” Its stability and efficacy make it a cornerstone for both Dermatology and Gynecology portfolios.
Therapeutic Profile: Primary Indications
Fluconazole is indicated for a wide range of fungal infections caused by Candida and Cryptococcus species.
| Indication | Clinical Context | Technical Rationale |
| Vaginal Candidiasis | Gynecology | The “Single Dose” (150 mg) treatment for yeast infections. |
| Mucosal Candidiasis | General Medicine | Treats Oropharyngeal (thrush) and Esophageal candidiasis in immunocompromised patients. |
| Dermatophytosis | Dermatology | Used for Tinea corporis (ringworm), Tinea cruris (jock itch), and Tinea pedis (athlete’s foot). |
| Onychomycosis | Dermatology | Long-term treatment for fungal nail infections. |
| Cryptococcal Meningitis | Critical Care | Used for both treatment and prophylaxis, especially in HIV/AIDS patients. |
Mechanism: The Ergosterol Depletion Strategy
Fluconazole works by sabotaging the “skin” (cell membrane) of the fungus:
Cytochrome P450 Inhibition: It technically inhibits the fungal enzyme 14-alpha-demethylase.
Blocking Ergosterol: This enzyme is required to convert lanosterol into Ergosterol, which is a vital component of the fungal cell membrane (similar to cholesterol in humans).
Membrane Disruption: Without ergosterol, the fungal cell membrane becomes leaky, leading to the accumulation of toxic precursors and the cessation of fungal growth (Fungistatic action).
The Pharmacist’s “Technical Warning”
Drug-Drug Interactions (CYP450): This is the most critical technical point for your B2B dossiers. Fluconazole is a potent inhibitor of human CYP2C9 and CYP3A4 enzymes. It can dangerously increase the blood levels of drugs like Warfarin (blood thinner), Sulfonylureas (diabetes), and Statins.
The “Single Dose” Advantage: For vaginal yeast infections, a single 150 mg capsule is technically sufficient because the drug has a long half-life ($t_{1/2} \approx 30\text{ hours}$).
Hepatotoxicity: While rare, long-term daily use requires monitoring of liver enzymes ($ALT/AST$).
QT Prolongation: Caution is required when prescribing to patients with existing heart rhythm issues.
The Manufacturer’s Perspective: Technical & Export
From the CEO’s desk at Healthy Life Pharma / Healthy Inc:
The “Bioequivalence” USP: On your digital marketplace, highlight that your Fluconazole 150 mg Capsules are bioequivalent to the innovator brand (Diflucan). High bioavailability is the hallmark of a well-formulated Fluconazole capsule.
The “Gyno-Pack” Strategy: Position your 150 mg capsules in Single-Tablet Blisters. This “Combi-Pack” (often paired with an antifungal cream) is a massive B2B seller for pharmacy chains in Africa and Southeast Asia.
Stability & Packaging: Fluconazole is relatively stable, but it is sensitive to light. We use PVC/PVDC-Opaque or Alu-Alu blistering to ensure the capsules remain potent over their 36-month shelf life.
Market Positioning: Position this as your “Infection Control Essential.” It is a high-demand item for hospital tenders, especially for intensive care units where secondary fungal infections are common.